1-6 of 6
Baptist Gallwitz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial

Open Access
Markku Laakso, Julio Rosenstock, Per-Henrik Groop, Anthony H. Barnett, Baptist Gallwitz, Uwe Hehnke, Ilkka Tamminen, Sanjay Patel, Maximilian von Eynatten, Hans-Juergen Woerle
Journal: Diabetes Care
Diabetes Care 2015;38(2):e15–e17
https://doi.org/10.2337/dc14-1684
Published: 10 January 2015
View article titled, Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial
Open the PDF for Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial in another window
Journal Articles

How Do We Continue Treatment in Patients With Type 2 Diabetes When Therapeutic Goals Are Not Reached With Oral Antidiabetes Agents and Lifestyle? Incretin versus insulin treatment

Open Access
Baptist Gallwitz, MD, Reinhard G. Bretzel, MD
Journal: Diabetes Care
Diabetes Care 2013;36(Supplement_2):S180–S189
https://doi.org/10.2337/dcS13-2012
Published: 17 July 2013
View article titled, How Do We Continue Treatment in Patients With Type 2 Diabetes When Therapeutic Goals Are Not Reached With Oral Antidiabetes Agents and Lifestyle? Incretin versus insulin treatment
Open the PDF for How Do We Continue Treatment in Patients With Type 2 Diabetes When Therapeutic Goals Are Not Reached With Oral Antidiabetes Agents and Lifestyle? Incretin versus insulin treatment in another window
Journal Articles

Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes: A randomized 26-week study on glycemic control and hypoglycemia

Open Access
Baptist Gallwitz, MD, Michael Böhmer, MD, Thomas Segiet, MD, Andrea Mölle, MD, Karsten Milek, MD, Bernd Becker, MD, Karin Helsberg, PHD, Helmut Petto, PHD, Natalie Peters, MSC, Oliver Bachmann, MD
Journal: Diabetes Care
Diabetes Care 2011;34(3):604–606
https://doi.org/10.2337/dc10-1900
Published: 17 February 2011
View article titled, Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes: A randomized 26-week study on glycemic control and hypoglycemia
Open the PDF for Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes: A randomized 26-week study on glycemic control and hypoglycemia in another window
Journal Articles

Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes: Understanding and implementing the International Diabetes Federation guidelines

Open Access
Baptist Gallwitz, MD
Journal: Diabetes Care
Diabetes Care 2009;32(suppl_2):S322–S325
https://doi.org/10.2337/dc09-S331
Published: 01 November 2009
View article titled, Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes: Understanding and implementing the International Diabetes Federation guidelines
Open the PDF for Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes: Understanding and implementing the International Diabetes Federation guidelines in another window
Journal Articles

Incretin-Based Therapies: Viewpoints on the way to consensus

Open Access
Michael. A. Nauck, MD, Tina Vilsbøll, MD, Baptist Gallwitz, MD, Alan Garber, MD, Sten Madsbad, MD
Journal: Diabetes Care
Diabetes Care 2009;32(suppl_2):S223–S231
https://doi.org/10.2337/dc09-S315
Published: 01 November 2009
View article titled, Incretin-Based Therapies: Viewpoints on the way to consensus
Open the PDF for Incretin-Based Therapies: Viewpoints on the way to consensus in another window
Journal Articles

Variation in the CDKAL1 Gene Is Associated With the Titer of Antibodies to GAD

Free
Axel Haupt, MD, Martina Guthoff, MD, Baptist Gallwitz, MD, Hans-Ulrich Haring, MD, Andreas Fritsche, MD
Journal: Diabetes Care
Diabetes Care 2008;31(9):e66
https://doi.org/10.2337/dc08-0756
Published: 01 September 2008
View article titled, Variation in the CDKAL1 Gene Is Associated With the Titer of Antibodies to GAD
Open the PDF for Variation in the CDKAL1 Gene Is Associated With the Titer of Antibodies to GAD in another window